Tweet
Share
E-mailAssertio Holdings (NASDAQ: ASRT), a commercial-stage pharmaceutical company, has announced the closing of two registered direct offerings — both completed last month. On Feb. 9, 2021, Assertio closed sales of 22,600,000 shares of common stock; the shares were sold to certain institutional investors at $0.62 per share. The closing of this first registered direct offering totaled $14 million in gross proceeds for the company. The company closed on its second registered direct offering on Feb. 12, 2021. That offering was comprised of 35,000,000 shares of common stock, again sold to certain institutional investors. Those shares were purchased at $0.98 per share, representing a premium to market based on applicable Nasdaq “minimum price” rules. The second direct offering resulted in gross proceeds of ules $34.3 million for the company. In the announcement, Assertio noted that it plans to use the net proceeds from both registered direct offerings for general corporate purposes, including general working capital. Sole placement agent for both direct offerings was Roth Capital Partners.
To view the full press release, visit https://ibn.fm/KBCbV
About Assertio Holdings Inc.
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers and acquisitions. For more information about the company, please visit www.AssertioTX.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.
